News from the FDA/CDC

FDA: PrEP indication updated to include adolescents at risk of HIV infection


 


2.2 HIV-1 screening for individuals receiving Truvada for HIV-1 PrEP

Screen all patients for HIV-1 infection before initiating Truvada for HIV-1 PrEP and at least once every 3 months while taking Truvada

2.5 Recommended dosage for HIV-1 PrEP

The dosage of Truvada in HIV-1 uninfected adults and adolescents weighing at least 35 kg is one tablet (containing 200 mg of FTC and 300 mg of TDF) once daily taken orally with or without food.

Pages

Recommended Reading

FDA approves raltegravir for newborns at risk for HIV-1 infection
MDedge Pediatrics
Teens with PID underscreened for HIV, syphilis
MDedge Pediatrics
HHS creates new religious freedoms division
MDedge Pediatrics
Trial seeks improved regimens for pregnant women with HIV
MDedge Pediatrics
nPEP for HIV: Updated CDC guidelines available for primary care physicians
MDedge Pediatrics
FDA approves complete combo tablet for HIV
MDedge Pediatrics
Time to HIV rebound in infants off ART linked to birth health
MDedge Pediatrics
MDedge Daily News: Can androgen therapy improve male frailty?
MDedge Pediatrics
Emotional regulation training lowers risk of adolescents having sex
MDedge Pediatrics
FDA seeks comments on pediatric HIV product development
MDedge Pediatrics